These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 29366653)

  • 1. Discovery of selective 2,4-diaminoquinazoline toll-like receptor 7 (TLR 7) agonists.
    Pieters S; McGowan D; Herschke F; Pauwels F; Stoops B; Last S; Embrechts W; Scholliers A; Mostmans W; Van Dijck K; Van Schoubroeck B; Thoné T; De Pooter D; Fanning G; Rosauro ML; Khamlichi MD; Houpis I; Arnoult E; Jonckers THM; Raboisson P
    Bioorg Med Chem Lett; 2018 Feb; 28(4):711-719. PubMed ID: 29366653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2,4-Diaminoquinazolines as Dual Toll-like Receptor (TLR) 7/8 Modulators for the Treatment of Hepatitis B Virus.
    Embrechts W; Herschke F; Pauwels F; Stoops B; Last S; Pieters S; Pande V; Pille G; Amssoms K; Smyej I; Dhuyvetter D; Scholliers A; Mostmans W; Van Dijck K; Van Schoubroeck B; Thone T; De Pooter D; Fanning G; Jonckers THM; Horton H; Raboisson P; McGowan D
    J Med Chem; 2018 Jul; 61(14):6236-6246. PubMed ID: 29965759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective Toll-like receptor 7 agonists with novel chromeno[3,4-d]imidazol-4(1H)-one and 2-(trifluoromethyl)quinoline/ quinazoline-4-amine scaffolds.
    Dolšak A; Švajger U; Lešnik S; Konc J; Gobec S; Sova M
    Eur J Med Chem; 2019 Oct; 179():109-122. PubMed ID: 31247373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Pyrimidine Toll-like Receptor 7 and 8 Dual Agonists to Treat Hepatitis B Virus.
    McGowan D; Herschke F; Pauwels F; Stoops B; Last S; Pieters S; Scholliers A; Thoné T; Van Schoubroeck B; De Pooter D; Mostmans W; Khamlichi MD; Embrechts W; Dhuyvetter D; Smyej I; Arnoult E; Demin S; Borghys H; Fanning G; Vlach J; Raboisson P
    J Med Chem; 2016 Sep; 59(17):7936-49. PubMed ID: 27513093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of tetrahydropyridopyrimidine based Toll-Like Receptor (TLR) 7/8 dual agonists.
    McGowan DC; Herschke F; Khamlichi MD; Rosauro ML; Benedicto SMP; Pauwels F; Stoops B; Pande V; Scholliers A; Van Schoubroeck B; Mostmans W; Van Dijck K; Thoné T; Horton H; Fanning G; Jonckers THM; Raboisson P
    Bioorg Med Chem Lett; 2018 Oct; 28(19):3216-3221. PubMed ID: 30143425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification and Optimization of Pyrrolo[3,2-d]pyrimidine Toll-like Receptor 7 (TLR7) Selective Agonists for the Treatment of Hepatitis B.
    McGowan DC; Herschke F; Pauwels F; Stoops B; Smyej I; Last S; Pieters S; Embrechts W; Khamlichi MD; Thoné T; Van Schoubroeck B; Mostmans W; Wuyts D; Verstappen D; Scholliers A; De Pooter D; Dhuyvetter D; Borghys H; Tuefferd M; Arnoult E; Hong J; Fanning G; Bollekens J; Urmaliya V; Teisman A; Horton H; Jonckers THM; Raboisson P
    J Med Chem; 2017 Jul; 60(14):6137-6151. PubMed ID: 28671847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and optimization of pteridinone Toll-like receptor 7 (TLR7) agonists for the oral treatment of viral hepatitis.
    Roethle PA; McFadden RM; Yang H; Hrvatin P; Hui H; Graupe M; Gallagher B; Chao J; Hesselgesser J; Duatschek P; Zheng J; Lu B; Tumas DB; Perry J; Halcomb RL
    J Med Chem; 2013 Sep; 56(18):7324-33. PubMed ID: 23961878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the adjuvant effect of agonists of toll-like receptor 4 and 7/8 in a vaccine against leishmaniasis in BALB/c mice.
    Rostamian M; Niknam HM
    Mol Immunol; 2017 Nov; 91():202-208. PubMed ID: 28963929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery and lead identification of quinazoline-based BRD4 inhibitors.
    Yang SM; Urban DJ; Yoshioka M; Strovel JW; Fletcher S; Wang AQ; Xu X; Shah P; Hu X; Hall MD; Jadhav A; Maloney DJ
    Bioorg Med Chem Lett; 2018 Nov; 28(21):3483-3488. PubMed ID: 30268702
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent and Prolonged Innate Immune Activation by Enzyme-Responsive Imidazoquinoline TLR7/8 Agonist Prodrug Vesicles.
    Wang B; Van Herck S; Chen Y; Bai X; Zhong Z; Deswarte K; Lambrecht BN; Sanders NN; Lienenklaus S; Scheeren HW; David SA; Kiessling F; Lammers T; De Geest BG; Shi Y
    J Am Chem Soc; 2020 Jul; 142(28):12133-12139. PubMed ID: 32524819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic cancer therapy with a small molecule agonist of toll-like receptor 7 can be improved by circumventing TLR tolerance.
    Bourquin C; Hotz C; Noerenberg D; Voelkl A; Heidegger S; Roetzer LC; Storch B; Sandholzer N; Wurzenberger C; Anz D; Endres S
    Cancer Res; 2011 Aug; 71(15):5123-33. PubMed ID: 21697281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toll-like receptor 7 selective synthetic oligoribonucleotide agonists: synthesis and structure-activity relationship studies.
    Lan T; Dai M; Wang D; Zhu FG; Kandimalla ER; Agrawal S
    J Med Chem; 2009 Nov; 52(21):6871-9. PubMed ID: 19824640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TLR7 tolerance is independent of the type I IFN pathway and leads to loss of anti-tumor efficacy in mice.
    Koga-Yamakawa E; Murata M; Dovedi SJ; Wilkinson RW; Ota Y; Umehara H; Sugaru E; Hirose Y; Harada H; Jewsbury PJ; Yamamoto S; Robinson DT; Li CJ
    Cancer Immunol Immunother; 2015 Oct; 64(10):1229-39. PubMed ID: 26091797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and characterization of a functional, alternatively spliced Toll-like receptor 7 (TLR7) and genomic disruption of TLR8 in chickens.
    Philbin VJ; Iqbal M; Boyd Y; Goodchild MJ; Beal RK; Bumstead N; Young J; Smith AL
    Immunology; 2005 Apr; 114(4):507-21. PubMed ID: 15804288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and characterization of new potent TLR7 antagonists based on analysis of the binding mode using biomolecular simulations.
    Pal S; Paul B; Bandopadhyay P; Preethy N; Sarkar D; Rahaman O; Goon S; Roy S; Ganguly D; Talukdar A
    Eur J Med Chem; 2021 Jan; 210():112978. PubMed ID: 33189437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
    Hamm S; Rath S; Michel S; Baumgartner R
    J Immunotoxicol; 2009 Dec; 6(4):257-65. PubMed ID: 19848448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and immunological activities of novel Toll-like receptor 7 and 8 agonists.
    Kandimalla ER; Struthers M; Bett AJ; Wisniewski T; Dubey SA; Jiang W; Precopio M; Sun Z; Wang H; Lan T; Agrawal S; Casimiro DR
    Cell Immunol; 2011; 270(2):126-34. PubMed ID: 21570062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats.
    Hammerbeck DM; Burleson GR; Schuller CJ; Vasilakos JP; Tomai M; Egging E; Cochran FR; Woulfe S; Miller RL
    Antiviral Res; 2007 Jan; 73(1):1-11. PubMed ID: 16959331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TLR agonist mediated suppression of allergic responses is associated with increased innate inflammation in the airways.
    Duechs MJ; Hahn C; Benediktus E; Werner-Klein M; Braun A; Hoymann HG; Gantner F; Erb KJ
    Pulm Pharmacol Ther; 2011 Apr; 24(2):203-14. PubMed ID: 21195789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel pyrimidine and malonamide derivatives as TGR5 agonists.
    Park EJ; Ahn YG; Jung SH; Bang HJ; Kim M; Hong DJ; Kim J; Suh KH; Kim YJ; Kim D; Kim EY; Lee K; Min KH
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4271-5. PubMed ID: 25082126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.